8-K: Bionomics Limited Announces Plan to Re-domicile to the United States via Scheme of Arrangement

Bionomics Limited plans to re-domicile from Australia to the United States by establishing a new parent company, Neuphoria Therapeutics Inc., in Delaware, subject to shareholder and regulatory approvals.

Summary

• Bionomics Limited, an Australian biotechnology company, intends to re-domicile to the United States by creating a new parent company, Neuphoria Therapeutics Inc., in Delaware.
• This re-domiciliation will be achieved through a scheme of arrangement, which requires approval from Bionomics shareholders and the Australian court.
• Upon completion, Bionomics will become a wholly-owned subsidiary of Neuphoria, and Neuphoria shares will replace Bionomics ADSs on the Nasdaq.
• Bionomics shareholders will receive one Neuphoria share for every 1,440 Bionomics ordinary shares or one Neuphoria share for every 8 Bionomics ADSs they hold.
• The re-domiciliation aims to reduce compliance costs, enhance visibility, and attract a broader range of investors.
• The company expects the share price of Neuphoria to be approximately US$3.5 per share if the proposed share consolidation ratio is applied to the current share price.
• The re-domiciliation is not expected to result in any material change to Bionomics' assets, management, operations, or strategy.
• The company anticipates a shareholder vote in late November 2024, with implementation of the scheme expected in early December 2024.

Sentiment

Score: 8

Explanation: The document conveys a positive outlook with a strategic move to enhance the company's position in the U.S. market. The re-domiciliation is presented as a value-maximizing decision, with clear benefits outlined. However, there are inherent risks and uncertainties associated with the process.

Positives

• The re-domiciliation is expected to eliminate significant Australian compliance costs.
• The move should increase alignment with prominent U.S. pharmaceutical companies, enhancing visibility and reputation.
• A U.S. corporate structure is expected to increase the company's attractiveness to potential strategic investors, merger partners, or acquirers.
• The re-domiciliation should improve marketability with U.S. institutional investors.
• It is expected to increase attractiveness to a broader U.S. investor pool.
• The simplified corporate structure should reduce administrative and compliance costs.
• Most online trading platforms will facilitate direct market access to trading U.S. shares post re-domiciliation.

Negatives

• The re-domiciliation requires shareholder and court approvals, which introduces uncertainty.
• The process involves legal and administrative complexities.
• There is a risk that the re-domiciliation may not be completed as planned.
• The indicative timetable is subject to change.

Risks

• The scheme of arrangement is subject to shareholder and court approvals, which may not be obtained.
• Regulatory approvals are required, and there is a risk that these may not be granted.
• The timetable for the re-domiciliation is indicative and subject to change.
• There is a risk that the expected benefits of the re-domiciliation may not be fully realized.
• The company is subject to the risks and uncertainties inherent in the biotechnology industry.

Future Outlook

The company anticipates a shareholder vote in late November 2024 and expects to implement the scheme in early December 2024, subject to approvals. The re-domiciliation is expected to enhance the company's visibility and attractiveness to investors.

Management Comments

• The Board is excited to enact this landmark unanimous decision in conjunction with our key shareholders and other stakeholders.
• It is a decision made with the intention to maximize shareholder value.
• By committing our presence to the United States, we believe that our Company's visibility to international investors will increase markedly.
• Very few Australian brokers can trade ADSs, however post the re-domiciliation, most online trading platforms facilitate direct market access to trading U.S. shares.

Industry Context

This re-domiciliation is a strategic move for Bionomics to align itself with the U.S. pharmaceutical market, where many of its peers are based. It reflects a trend of international companies seeking to establish a stronger presence in the U.S. market to attract investors and reduce compliance burdens.

Comparison to Industry Standards

• Many biotechnology companies, such as those listed on the Nasdaq, are incorporated in the US, particularly in Delaware, due to its favorable corporate laws.
• The move to consolidate shares is common for companies seeking to increase their share price and appeal to institutional investors, similar to other emerging biotech companies.
• The re-domiciliation is similar to other companies that have moved their primary listing to the US to access a larger pool of capital and investors, such as Jazz Pharmaceuticals which re-domiciled from Ireland to the US in 2012.
• The proposed share price of US$3.5 per share is within the range of other emerging biotech companies on the Nasdaq.

Stakeholder Impact

• Shareholders will receive shares in the new parent company, Neuphoria Therapeutics Inc.
• The re-domiciliation is expected to increase the company's visibility to international investors.
• The move is intended to maximize shareholder value.
• Employees are not expected to be materially impacted by the re-domiciliation.
• Customers and suppliers are not expected to be materially impacted by the re-domiciliation.
• Creditors are not expected to be materially impacted by the re-domiciliation.

Next Steps

• Bionomics shareholders will receive a Scheme Booklet with detailed information.
• A shareholder vote on the Scheme is expected in late November 2024.
• The Scheme is expected to be implemented in early December 2024, subject to approvals.
• Bionomics will apply to Nasdaq to have trading suspended in Bionomics ADSs and list Neuphoria Shares.

Key Dates

Keywords

re-domiciliation, scheme of arrangement, Neuphoria Therapeutics, Bionomics Limited, Nasdaq, biotechnology, share consolidation, corporate structure, US investors, compliance costs